CINECA IRIS Institutional Research Information System

DE NICOLO', Amedeo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.739
EU - Europa 4.340
AS - Asia 4.186
SA - Sud America 621
AF - Africa 116
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 8
Totale 18.039
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.602
SG - Singapore 1.886
CN - Cina 1.232
IT - Italia 979
DK - Danimarca 580
IE - Irlanda 476
BR - Brasile 468
SE - Svezia 430
DE - Germania 334
FR - Francia 323
VN - Vietnam 300
AT - Austria 278
FI - Finlandia 229
GB - Regno Unito 179
IN - India 169
UA - Ucraina 159
KR - Corea 152
HK - Hong Kong 94
ID - Indonesia 76
NL - Olanda 75
CA - Canada 69
JP - Giappone 53
AR - Argentina 51
ES - Italia 49
MX - Messico 45
PL - Polonia 45
CZ - Repubblica Ceca 38
BE - Belgio 36
RU - Federazione Russa 33
BD - Bangladesh 32
ZA - Sudafrica 31
AU - Australia 27
IQ - Iraq 27
CL - Cile 26
EG - Egitto 24
TH - Thailandia 23
GR - Grecia 20
CH - Svizzera 19
EC - Ecuador 19
TR - Turchia 18
CO - Colombia 15
PK - Pakistan 15
RO - Romania 15
UZ - Uzbekistan 15
VE - Venezuela 15
TW - Taiwan 12
MA - Marocco 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
NG - Nigeria 9
EU - Europa 8
IL - Israele 8
PE - Perù 8
SN - Senegal 8
JO - Giordania 7
LT - Lituania 7
PS - Palestinian Territory 7
PT - Portogallo 7
RS - Serbia 6
SA - Arabia Saudita 6
TN - Tunisia 6
UY - Uruguay 6
DZ - Algeria 5
GE - Georgia 5
MY - Malesia 5
CR - Costa Rica 4
JM - Giamaica 4
KE - Kenya 4
KG - Kirghizistan 4
AZ - Azerbaigian 3
BO - Bolivia 3
IR - Iran 3
LK - Sri Lanka 3
LV - Lettonia 3
NO - Norvegia 3
QA - Qatar 3
BF - Burkina Faso 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
ME - Montenegro 2
ML - Mali 2
MN - Mongolia 2
MO - Macao, regione amministrativa speciale della Cina 2
MW - Malawi 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
TT - Trinidad e Tobago 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
Totale 18.011
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.314
Singapore 1.045
Chandler 984
Beijing 621
Ashburn 585
Santa Clara 539
Dublin 475
Fairfield 341
Torino 312
Houston 293
Woodbridge 251
Nyköping 221
Vienna 217
Dearborn 195
Villeurbanne 190
Wilmington 184
Columbus 144
Medford 141
Turin 138
Princeton 133
Seattle 123
Los Angeles 118
Cambridge 116
Hefei 105
Fremont 102
Dallas 98
Seoul 97
Redwood City 96
Jacksonville 94
New York 90
Munich 89
Buffalo 75
Ho Chi Minh City 71
Hong Kong 70
Jakarta 59
Milan 54
Boardman 53
Boston 49
Hanoi 48
São Paulo 48
Dong Ket 43
Nuremberg 42
Redondo Beach 42
Turku 39
Bengaluru 38
Guangzhou 38
Pisa 37
Shanghai 36
Nanjing 35
The Dalles 34
Helsinki 33
Hangzhou 32
Warsaw 32
Washington 32
Brussels 29
Toronto 29
Brno 26
Tokyo 25
London 24
San Diego 23
Frankfurt am Main 22
Lappeenranta 22
Verona 21
Hebei 19
Mumbai 19
Silver Spring 19
Chengdu 18
Chicago 18
Norwalk 18
Rio de Janeiro 18
Düsseldorf 17
Rome 16
Belo Horizonte 15
Baghdad 14
Mexico City 14
Phoenix 14
Amsterdam 13
San Francisco 13
Zurich 13
Barcelona 12
Da Nang 12
Jinan 12
Orem 12
Stockholm 12
Brooklyn 11
Cairo 11
Falkenstein 11
Genoa 11
Hyderabad 11
Mountain View 11
Zhengzhou 11
Falls Church 10
Pune 10
Atlanta 9
Central District 9
Cinisello Balsamo 9
Guarulhos 9
Poplar 9
Tianjin 9
Abuja 8
Totale 11.189
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 456
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 446
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 284
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 275
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 268
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 261
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 235
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 228
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 222
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 220
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 219
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 212
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study 211
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 199
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 198
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 196
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 192
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 189
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 189
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 184
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 183
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 181
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 179
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 178
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells 177
Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period 177
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 173
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 172
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 172
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 171
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 169
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 168
Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration 166
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 166
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 165
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 164
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 161
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 159
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 158
Pharmacogenetics of ribavirin-induced anemia in HCV patients 155
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 147
Cannabinoids concentration variability in cannabis olive oil galenic preparations 147
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 146
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? 144
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 142
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 137
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 135
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 134
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 132
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients 131
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 130
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 129
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 128
A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring 128
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 125
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 123
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration 122
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients 122
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 121
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 120
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 120
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 118
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 117
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 117
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 116
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 116
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 115
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 113
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 113
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 112
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 112
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 111
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 110
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma 110
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 108
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 107
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 105
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 104
UHPLC-MS/MS Method with On-line SPE to Quantify Tacrolimus and Everolimus in Peripheral Blood Mononuclear Cells: Application of “IS-normalized” Matrix Effect 102
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 102
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples 102
Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients 102
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 101
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 101
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients 101
A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients 100
Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in plasma: Implementation in a LC-MS/MS Kit 99
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 98
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump 97
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 97
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 96
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 96
Therapeutic drug monitoring guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence 96
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting 95
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 95
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 94
Seasonal variation of antiretroviral drug exposure during the year: The experience of 10 years of therapeutic drug monitoring 90
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 88
A new UHPLC-MS/MS method for cannabinoids determination in human plasma: A clinical tool for therapeutic drug monitoring 87
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 86
Totale 15.070
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.231
article - articoli 0
book - libri 0
conference - conferenze 8.303
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.534
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021958 0 0 0 0 0 104 107 52 105 115 191 284
2021/20222.447 176 193 196 196 156 213 181 152 114 129 388 353
2022/20232.773 249 234 71 258 253 659 164 230 315 61 182 97
2023/20241.120 154 194 78 54 64 152 28 51 13 59 103 170
2024/20253.237 52 154 133 285 798 246 82 156 359 196 286 490
2025/20263.065 785 350 413 791 684 42 0 0 0 0 0 0
Totale 18.715